Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on MRNS. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, September 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Jefferies Financial Group reissued a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Down 0.1 %

Shares of MRNS opened at $0.53 on Friday. The firm has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $11.26. The stock has a market capitalization of $29.43 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of MRNS. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the period. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $64,000. World Investment Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 117,255 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.